Business Wire

ASM Global’s Savor Team USA Heads to Singapore to Vie for Global Title in World’s Only Young Chef Young Waiter and Mixologist Competition

Share

ASM Global’s culinary division SAVOR, which provides elevated food experiences for the globe’s most prestigious arenas, stadiums, convention/exhibition centers and performing arts venues, has announced the national winners of the American round of the world’s only competition for young culinary and hospitality talent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240809474691/en/

Mixologist Winner Marco Guillen, Four Seasons, Napa Valley, California. (Photo: Business Wire)

Thomas Mendel, chef from Hamel Winery; Jaclyn Bisantz, waitress from Harbor House; and Marco Guillen, mixologist from Four Seasons Napa, were crowned as winners of the U.S. leg of the renowned World Young Chef Young Waiter Young Mixologist (WorldYYY) competition — the only event of its kind.

“This syncs very nicely with the work ASM Global does nationally to develop deep relationships with our local communities and reach out to educate, train and employ culinary talent via scholarship, internship and apprenticeship programs,” said Shaun Beard, SAVOR’s senior vice present of food and beverage.

“As ASM Global continues to elevate the food experience in many of the world’s premiere venues, these up-and-coming talents will be part of our universe,” Beard said. “The composure, creativity and determination we’ve seen from all the competitors in this high-pressure situation was truly unmatched and is proof that we have so much to look forward to from these young stars. We are proud to help pave the way for them and are excited to see what they do next.”

SAVOR’s Team USA members will next compete in the WorldYYY finals at Swissôtel The Stamford in Singapore this November. They will showcase their abilities to world-class chefs, hospitality experts and esteemed mixologists. A total of 36 contestants from 12 countries will compete for the world titles of Best Young Chef, Young Waiter and Young Mixologist.

The finals ofYYY USA recently took place at the prestigious The Culinary Institute of America at Copia (CIA) in Napa, California, with a panel of expert judges, including Master Chef Roland Passot, propriétaire and chief culinary officer; Tournament of Champions’ Tracey Shepos Cenami, executive chef and cheese specialist at Kendall-Jackson Wine Estate and Gardens; and Food Network Chef Adam Sobel, partner of Mina Group anointing the winners.

ASM Global’s SAVOR division became a strategic partner of the competition nearly five years ago as part of its worldwide commitment to nurturing and identifying new talent, introducing them to the hospitality space and showcasing them to renowned culinary industry leaders.

About SAVOR

SAVOR is the culinary division of ASM Global, the world’s No. 1 development and full-service venue company with a portfolio of more than 400 of the world’s most prestigious arenas, stadiums, convention/exhibition centers and performing arts venues network spanning five continents. The team at SAVOR provides elevated and curated guest experiences at every event, from the food preparation to the beverage offerings, whether for intimate VIP experiences or banquets with over 20,000 guests. In addition to authentic, chef-driven food, the core elements of SAVOR's food vision include partnerships with local growers, producers and community members; a commitment to using antibiotic-free meats and poultry; and dedication to minimizing impact on the environment through robust sustainability, recycling and composting programs. For more information, please visit savorasmglobal.com.

About YYY

Since its establishment in 1979, the Young Chef Young Waiter competition has continued to promote hospitality as a career of choice, a profession and a vocation. Today, with its new revitalized format, Young Chef Young Waiter continues to honor the next culinary and service stars globally. World Young Chef Young Waiter Young Mixologist’s, in partnership with Great Campaign U.K. and Northern Ireland and The Culinary Institute of America, mission is to discover the best young talents in the industry. The competition is open to young chefs, waiters and mixologists age 28 and under from diverse backgrounds. YYY ensures these young talents are equipped with relevant skills, current knowledge and a network to help them succeed in the world of hospitality.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240809474691/en/

Contacts

Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
Mobile: 818-264-6812

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye